نتایج جستجو برای: tyrosine kinase inhibitors
تعداد نتایج: 417183 فیلتر نتایج به سال:
Frontline acute myeloid leukemia (AML) treatment is determined by a combination of patient and genetic factors. This includes fitness (i.e., comorbidities that increase the risk treatment-related mortality) characteristics, including cytogenetic events gene mutations. In older unfit patients, standard care typically venetoclax (VEN) combined with hypomethylating agents (HMA). Recently, several ...
BACKGROUND Second-generation tyrosine kinase inhibitors induce cytogenetic responses in approximately 50% of patients with chronic myeloid leukemia in chronic phase in whom imatinib treatment has failed. However, it has not yet been established which of the patients in whom imatinib treatment fails are likely to benefit from therapy with second-generation tyrosine kinase inhibitors. DESIGN AN...
Current standard treatments for patients with metastatic (stage IV) renal cell carcinoma involve both surgical removal of tumors and treatment with biological agents such as interleukin 2 and/or IFN-alpha. Unfortunately, such approaches are inadequate for most patients with stage IV disease; the result is a median time to progression of 2 to 4 months and an overall survival of 6 to 17 months. S...
Conventional cytotoxic chemotherapy involving DNA-interacting agents and indiscriminate cell death is no longer the future of cancer management. While chemotherapy is not likely to completely disappear from the armamentarium; the use of targeted therapies in combination with conventional treatment is becoming the standard of care in human medicine. Tyrosine kinases are pivotal points of functio...
The development of tyrosine phosphorylation inhibitors has transformed the approach to cancer therapy and is likely to affect other fields of medicine. In spite of the conservation among protein tyrosine kinases (PTKs), one can develop small molecules that block the activity of a narrow spectrum of PTKs and that exhibit much less toxicity than the currently used chemotherapeutic agents. In this...
Gleevec (imatinib), are among the most broadly applied cancer therapeutics. By blocking the tyrosine kinase activity of mutated or overexpressed oncogenes, such as Epidermal Growth Factor Receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), they interfere with signaling cascades which cancer cells are frequently " addicted " to, inducing vigorous and prolonged clinical responses...
Ma Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder, characterized by proliferation of granulocytes, caused by a translocation that produces the Philadelphia chromosome resulting in constitutively active BCR-ABL tyrosine kinase. Imatinib and dasatinib are 2 BCR-ABL tyrosine kinase inhibitors (TKI) used in the treatment of CML. Since the introduction of dasatinib earlier th...
Jawad Francis, MD,1 Manmeet S. Ahluwalia, MD,2 Meir Wetzler, MD,2 Eunice Wang, MD,2 Pamela Paplham, RN, FNP,2 Shannon Smiley, MD,2 Philip L. McCarthy, MD,2 I. Larry Cohen, MD,3 Edward Spangenthal, MD,2 and Minoo Battiwalla, MD2 1Department of Medicine, State University of New York at Buffalo, Buffalo, New York; 2Department of Medicine, 3Department of Anesthesiology and Pain Medicine, Roswell Pa...
Until few years ago non-specific cytotoxic agents were considered the tip of the arrow as first line treatment for lung cancer. However; age > 75 was considered a major drawback for this kind of therapy. Few exceptions were made by doctors based on the performance status of the patient. The side effects of these agents are still severe for several patients. In the recent years further investiga...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید